chr1-46192168-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The ENST00000371984.8(POMGNT1):c.1469G>A(p.Cys490Tyr) variant causes a missense change. The variant allele was found at a frequency of 0.0000508 in 1,614,032 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C490G) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000371984.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POMGNT1 | NM_017739.4 | c.1469G>A | p.Cys490Tyr | missense_variant | 17/22 | ENST00000371984.8 | NP_060209.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POMGNT1 | ENST00000371984.8 | c.1469G>A | p.Cys490Tyr | missense_variant | 17/22 | 1 | NM_017739.4 | ENSP00000361052 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152196Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251488Hom.: 0 AF XY: 0.0000294 AC XY: 4AN XY: 135922
GnomAD4 exome AF: 0.0000520 AC: 76AN: 1461836Hom.: 0 Cov.: 31 AF XY: 0.0000481 AC XY: 35AN XY: 727222
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152196Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74362
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 25, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2024 | POMGNT1: PM3:Very Strong, PM1, PM2, PP3, PP4, PS3:Supporting - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 10, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18195152, 17559086, 21361872, 19067344, 15466003, 17906881, 22323514, 24282183, 17878207, 17030669, 31589614) - |
Muscle eye brain disease Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Oct 17, 2016 | - - |
Muscular dystrophy-dystroglycanopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 24, 2023 | The p.Cys490Tyr variant in POMGNT1 has been reported in 8 individuals with POMGNT1-associated muscular dystrophy-dystroglycanopathy (PMID: 15466003, 22323514, 17559086, 24282183, 17030669), and has been identified in 0.006% (2/35440) of Latino/Admixed American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: dbSNP ID rs267606960). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID #4000) and has been interpreted as pathogenic by Invitae, Fulgent Genetics, CeGaT Center for Human Genetics Tuebingen, OMIM, and Natera, Inc, and as likely pathogenic by PerkinElmer Genomics and Counsyl. Of these 8 affected individuals, 3 were homozygotes, and at least 1 was a compound heterozygote that carried a pathogenic variant in trans, which increases the likelihood that the p.Cys490Tyr variant is pathogenic (PMID: 15466003, 22323514, 17559086, 24282183; ClinvarID: 265399). In vitro functional studies provide some evidence that the p.Cys490Tyr variant may impact protein function, as reflected by reduced catalytic activity in an in vitro enzymatic activity assay (PMID: 21361872). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for POMGNT1-associated muscular dystrophy-dystroglycanopathy. ACMG/AMP Criteria applied: PM3_Strong, PM2_supporting, PS3_Supporting, PP3 (Richards 2015). - |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3;C3150417:Autosomal recessive limb-girdle muscular dystrophy type 2O;C3151519:Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3;C4310704:Retinitis pigmentosa 76 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jul 27, 2021 | - - |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3;C3150417:Autosomal recessive limb-girdle muscular dystrophy type 2O Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 490 of the POMGNT1 protein (p.Cys490Tyr). This variant is present in population databases (rs267606960, gnomAD 0.006%). This missense change has been observed in individual(s) with congenital muscular dystrophy, cobblestone lissencephaly, and muscle-eye-brain (MEB) disease (PMID: 15466003, 17030669, 17559086, 17878207, 22323514, 24282183). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4000). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on POMGNT1 protein function. Experimental studies have shown that this missense change affects POMGNT1 function (PMID: 21361872). For these reasons, this variant has been classified as Pathogenic. - |
POMGNT1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 14, 2024 | The POMGNT1 c.1469G>A variant is predicted to result in the amino acid substitution p.Cys490Tyr. This variant has been reported in homozygous and compound heterozygous states in individuals with POMGNT1-related disorders (Diesen et al. 2004. PubMed ID: 15466003; Raducu et al. 2013. PubMed ID: 24282183; Biancheri et al. 2006. PubMed ID: 17030669; Godfrey et al. 2007. PubMed ID: 17878207; Bouchet et al. 2007. PubMed ID: 17559086). A functional study showed the p.Cys490 substitution does not decrease protein expression, but does cause reduced catalytic activity (Voglmeir et al. 2011. PubMed ID: 21361872). This variant is reported in 0.0056% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic. - |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2008 | - - |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 26, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at